BCN Peptides

Quick facts

Phase 2 pipeline

• COLIRIOBCN070660
  COLIRIOBCN070660 is a peptide-based therapeutic candidate developed by BCN Peptides, currently in phase 2 clinical development.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BCN Peptides portfolio CI brief
• BCN Peptides pipeline updates RSS